Helix BioPharma Corp. Closes Second Tranche of Private Placement

    NEXT STORY
    Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors
    PREV STORY
    Alimera Sciences Announces First Quarter 2019 Financial Results and Provides Corporate Overview
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Applied Therapeutics Announces Launch of Galactosemia Awareness and Education Initiative

    author_avatar
    NASDAQ Market News

    CytomX Announces First Quarter 2017 Financial Results

    SOUTH SAN FRANCISCO, Calif., May 05, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), ...

    author_avatar
    NASDAQ Market News

    Point-of-Care Diagnostics Market for Infectious Diseases, 2020-2025

    author_avatar
    NASDAQ Market News